Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SF enters its October 21 earnings report carrying a 14% one-month decline, a cluster of freshly cut price targets, and options activity edging more cautious, yet the borrow market tells a story of almost complete indifference from short sellers.
The dominant narrative this week is the analyst target resets. Three firms moved in the same direction in the past two days, all lowering targets while holding ratings unchanged. UBS cut from $90 to $84 but kept its Buy. JP Morgan trimmed from $86 to $82 at Neutral. BMO Capital made the sharpest move, pulling its target from $85 to $75, which sits within a few dollars of where the stock is trading now at $70.12. The Street mean is $85.25, implying around 21% upside at current levels, but the direction of travel is clearly downward. No firm has upgraded or initiated positively in the recent window, and the consensus has been drifting lower since the start of the year. None of this is a panic; it reads more like the Street recalibrating around a difficult rate and capital markets backdrop that has taken SF down nearly 14% in a month.
Options positioning has shifted incrementally more defensive heading into the print. The put/call ratio is running at 0.20, well above its 20-day average of 0.15, placing the reading about 1.6 standard deviations above recent norms. That is not an extreme reading by any measure, the 52-week high in the PCR is 3.6, but the trend over the past two weeks is clear: puts have been accumulating steadily since late September. Short interest, by contrast, is barely a factor here. SF's SI is about 4.4% of free float, and it has been drifting lower all week, down roughly 2% over seven days. Borrow costs remain trivial at 0.51%, up about 19% on the week in percentage terms but still an absolute number that signals no real demand for shorts. Shares available to borrow are extraordinarily plentiful, with no tightening visible in the lending pool at all. The two signals point in opposite directions: options traders are modestly more cautious, short sellers are not pressing.
The valuation picture supports the idea that SF is cheaper than it has been, though not obviously cheap in isolation. The PE has compressed by about 1.6 turns over the past month to just under 10x. Price-to-book is at 1.69, also lower over 30 days by around 0.27. For a profitable broker-dealer with a strong balance sheet, those multiples are not demanding. The ORTEX factor scores reflect mixed signals: dividend quality ranks in the 99th percentile, the days-to-cover rank sits at 71, and EPS surprise ranks at 61, reflecting a company that tends to beat estimates. Against that, 30-day EPS momentum is weak at 36, and the 12-month forward EPS growth score of 32 suggests the Street is not expecting a sharp acceleration in earnings.
The alt-data picture adds one data point worth noting without overstating it. FDIC call report data shows SF's insured bank charters recorded their largest Q2 total assets on record at $35.5 billion, and largest Q2 total deposits on record at $32.3 billion, both for the period ending April 2026. These are verified record readings from the Federal Deposit Insurance Corporation. The dataset has not yet accumulated enough history for ORTEX to test whether it leads the company's reported net income, so no leading-indicator claim can be made. The record deposit base does illustrate that the banking subsidiary continued expanding through the period, even as the parent company's equity has been under pressure.
Institutional ownership gives little obvious signal. BlackRock holds close to 10% of shares, FMR around 5.6%, and both added shares in the most recent reporting period. FMR's 13G/A filed in November 2025 showed a reduction from 9.1% to 5.7%, a meaningful trim worth noting, though that is as-last-disclosed data and positions may have moved further. No 13D activist is on the register.
The last earnings release, in late July, produced a 2.5% one-day gain and a 5.6% five-day gain, suggesting the stock rewarded a positive print. Whether the more cautious pre-earnings options tone and the string of analyst target cuts this week reflect a shift in expectations ahead of October 21 is the question the next print will answer.
See the live data behind this article on ORTEX.
Open SF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
